Member Info for RustyJames

im down a little on hvivo but this is ****e..

business model has changed 3 times since it was first listed

I bet existing shareholders are dumping as well after being diluted by almost 100%..

Volume will be non existent here in a few days so the window to unload is short..

I bet the funds that got in at 6p are already unloading..

So you've traded out again Hotchip🙄..

I bet some of the hedge funds are unloading on suckers already.

As was expected existing shareholders screwed and diluted by close to 100%..

Same as Poolbeg keep diluting.

Shell game.

All we can go on it the CFO said(in the last investor podcast ) that Iliad were in situ preparing for the trial.

Thats was before the raised the $115 million..

Naw dont think so..they would have initiated selling much higher and have sold alot more by now.

Looking at trading today here's hoping for a signed contract soon

Someone is still unloading..Frustrating

10%

So they only sold (1%) 7 million shares after all that..

For hVIVO, a world leader in human challenge trials (HCTs) and early-phase clinical research, the new MHRA regulations coming in April 2026 are a significant competitive advantage.

The company has explicitly stated it is a "working partner" with the Office for Life Sciences to support this sector-wide plan.

hVIVO

Strategic Impact on hVIVO Operations

Drastic Reduction in Setup Times: hVIVO expects the new framework to help reduce trial setup times from roughly 250 days to under 150 days by 2026.

14-Day Phase I Fast-Track: As a specialist in early-phase research, hVIVO will benefit directly from the new 14-day assessment route for Phase I trials. This allows them to move "healthy volunteer" trials into their quarantine facilities much faster than before.

Global Competitive Edge: The CEO, Yamin 'Mo' Khan, has noted that these reforms make the UK a more attractive destination for global pharmaceutical clients. This supports hVIVO’s current "largest ever sales pipeline," which includes high-value contracts like the world’s first Phase III human challenge trial.

Innovative Trial Designs: The 2026 regulations formally embrace adaptive trial designs and computer simulations. This aligns with hVIVO’s strategy to use its hLAB services and data-driven insights to "fail fast or succeed fast" for clients

Yes DILUTION.The share trading range was 5.5p-6p,so the capital raise will be within that range or lower

and they'll be coming back for more..

Yep millions of shares up for sale again.

Who the hell is selling?

You're right sorry it was June 2024 they contracted Emmes.

I thought it was June 2025..

Sorry

Problem now is people will get anxious the longer we have to wait for the news to hit the wires.

Emmes Group have a contract already signed.

If they could land another smaller HCT contract before Iliad's it would be transformative.

There's gotta be something in the pipeline.

For the ongoing Phase III ANCHOR trial of CD388 (now owned by Merck/MSD), hVIVO is performing a dual role as both a primary clinical site and the central laboratory hub.

1. Central Virology Laboratory (hLAB)

hVIVO’s laboratory division, hLAB, is responsible for the technical analysis and logistical management of the entire global trial:

Primary Endpoint Analysis: Conducting the core virology and immunology tests to determine the vaccine's efficacy across all 6,000 participants.

Sample Logistics: Managing the collection and international transport of tens of thousands of respiratory swabs and antibody samples from over 150 sites worldwide.

Assay Development: Preparing specialized sample collection kits and providing scientific consultancy for the trial's design.

2. Clinical Site Services

Beyond laboratory work, hVIVO is serving as a major clinical site for participant recruitment and dosing:

UK Recruitment: In the previous Phase IIb study, hVIVO was the only UK site and achieved the highest recruitment numbers globally, dosing over 800 people in just six weeks.

Phase III Site: They continue this role in Phase III, utilizing their FluCamp volunteer database to rapidly enroll high-risk and elderly participants in the UK.

3. Strategic Continuity

hVIVO has worked on the CD388 program through every stage of its development:

Phase IIa: Conducted the early proof-of-concept Human Challenge Trial (HCT) that first proved the drug's effectiveness.

Phase IIb: Acted as the central lab and lead recruitment site.

Phase III: Currently delivering the most significant laboratory support contract in its history to date.

Since hVIVO is handling all 60,000+ samples for this trial, would you like to know more about the capacity of their new Canary Wharf lab to process these results for the upcoming Q1 interim analysis?

AI responses may include mistakes. Learn more

hVIVO hails $9.2 billion Cidara takeover after key trial wins

Proactive Investors·Ian Lyall

MSD to acquire Cidara after positive phase 2b trial results - PharmaTimes

PharmaTimes

hVIVO welcomes MSD's move to acquire Cidara in $9.2 billion deal - Vox Markets

Vox Markets

Show all

I know Cathal Friel is a chancer but I do respect the other management in Poolbeg.

Sorry for the off topic

Thetadecay..question off topic..

POLB-001 yeah or nay or too early to call?